Information Provided By: 
Fly News Breaks for November 9, 2017
IDRA
Nov 9, 2017 | 12:30 EDT
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
News For IDRA From the Last 2 Days
There are no results for your query IDRA
